Given the impact of heparanase on tumor angiogenesis and metastasis [44] and the anti-metastatic activity of HS mimetics/heparanase inhibitors [20], [23], [25], [27], [28], [45], [46], PG545 was investigated in the 4T1 mastectomy model using sorafenib as an antiangiogenic comparator agent. Here, HPSE is linked to neoplasm.